6533b82cfe1ef96bd128ec7c

RESEARCH PRODUCT

Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1

ÖZlem TüreciUlrich MackUgur SahinMartina SesterHelma HeinenFrank KrummenauerUlrich LuxemburgerGerhard W. SybrechtUrban Sester

subject

MaleCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsAntibodies NeoplasmEnzyme-Linked Immunosorbent AssayAdenocarcinomaAntigenAntigens NeoplasmCarcinoma Non-Small-Cell LungmedicineHumansCarcinoma Small CellLung cancerAgedAutoantibodiesbiologybusiness.industryAutoantibodyMembrane ProteinsCancerCell DifferentiationMiddle Agedmedicine.diseaseTumor antigenrespiratory tract diseasesOncologyCarcinoma Squamous Cellbiology.proteinAdenocarcinomaFemaleAntibodyNY-ESO-1business

description

The cancer-associated antigen NY-ESO-1 is expressed in a number of malignancies of different histological type. Patients with NY-ESO-1 expressing tumors have been shown to bear circulating autoantibodies against this antigen. In this study, we have assessed the NY-ESO-I autoantibody response in patients with lung cancer by a serum ELISA. Using a serum dilution of 1:400 we detected seroreactivity in 35 of 175 (20%) of patients. Incidence of autoantibodies was significantly higher in patients suffering from non small cell lung cancer (NSCLC, 23%) as compared to those with small cell lung cancer (SCLC, 9%). In the NSCLC group, NY-ESO-I antibody was significantly more frequent in patients with undifferentiated tumors (40%) as compared to patients with either adenocarcinoma or squamous cell carcinoma (15 and 29%). Our observations indicate that induction of NY-ESO-I autoantibodies depends on the histological subtype within a given tumor entity.

yearjournalcountryeditionlanguage
2005-02-14Cancer Letters
https://doi.org/10.1016/j.canlet.2005.05.008